{"name":"Millennium Pharmaceuticals, Inc.","slug":"millennium-pharmaceuticals-inc","ticker":"","exchange":"","domain":"millennium.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"VELCADE Administered by intravenous infusion","genericName":"VELCADE Administered by intravenous infusion","slug":"velcade-administered-by-intravenous-infusion","indication":"Multiple myeloma","status":"phase_3"},{"name":"TAK-788","genericName":"TAK-788","slug":"tak-788","indication":"Non-small cell lung cancer with EGFR exon 20 insertion mutations","status":"phase_3"},{"name":"VELCADE Administered by subcutaneous injection","genericName":"VELCADE Administered by subcutaneous injection","slug":"velcade-administered-by-subcutaneous-injection","indication":"Multiple myeloma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"CT53518","genericName":"CT53518","slug":"ct53518","indication":"Other","status":"phase_1"},{"name":"MLN518","genericName":"MLN518","slug":"mln518","indication":"Other","status":"phase_1"},{"name":"Oral cholera vaccine","genericName":"Oral cholera vaccine","slug":"oral-cholera-vaccine","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"VELCADE Administered by intravenous infusion","genericName":"VELCADE Administered by intravenous infusion","slug":"velcade-administered-by-intravenous-infusion","phase":"phase_3","mechanism":"VELCADE (bortezomib) is a proteasome inhibitor that blocks the degradation of proteins, causing cancer cells to accumulate toxic protein levels and undergo apoptosis.","indications":["Multiple myeloma","Mantle cell lymphoma"],"catalyst":""},{"name":"CT53518","genericName":"CT53518","slug":"ct53518","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MLN518","genericName":"MLN518","slug":"mln518","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oral cholera vaccine","genericName":"Oral cholera vaccine","slug":"oral-cholera-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"TAK-788","genericName":"TAK-788","slug":"tak-788","phase":"phase_3","mechanism":"TAK-788 is a selective inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion mutations.","indications":["Non-small cell lung cancer with EGFR exon 20 insertion mutations"],"catalyst":""},{"name":"VELCADE Administered by subcutaneous injection","genericName":"VELCADE Administered by subcutaneous injection","slug":"velcade-administered-by-subcutaneous-injection","phase":"phase_3","mechanism":"VELCADE is a proteasome inhibitor that blocks the action of proteasomes in cells, leading to cell death.","indications":["Multiple myeloma","Mantle cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNSWZ4SnBhLVBPSmgzOTcyQVBkcllqb2pDQnlfSUtVVkxHVmgtSElPeDRaOTRJbGZpRlZMS3UtR0NGWXZsT2V5aGNNbFYxQ3BObGprbjY5UlZCaUtndUt0YzZHUC1rejdHS3dNa1A4MHprRzNjSEV5UmdxdE55Qkcxc2Nna1I0Sm52dU5mZlNsQUU3UWlvdG5jetIBWEFVX3lxTFBxQ3NiRDR3c190dTZDUFQtTEQ5S3kxM3BNNmhPQlBfaTNjNTVJTWdIeW5IcWprUzNRYjhYbUFYUGRpWGtkTEJZXzhtbDZtUGh0cU4ya3JxbzU?oc=5","date":"2026-04-07","type":"patent","source":"Law360","summary":"Advanz Takes Aim At Rival's Bowel Disease Drug Patent - Law360","headline":"Advanz Takes Aim At Rival's Bowel Disease Drug Patent - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxON0J2eXpqUkY2YjVIbmhxN21BNTlyMzBMRHBybW0yLVBqbTNnRDlFdDQzOXN5UGRBWHFQRDIxSXFjbVp6Sk51VldlRUx6SnZOMjN0YkU2Rl9HaUJIRnJtUzFKWUltTWoxQkhBeVVhX1ZlVDhoRTdYT0RtOEFSRmoxR1htampYV3RsaHNfdVl0MnN4OVVkMktXdVFzNV9BWkXSAVZBVV95cUxOZzV4RVhZN2ZycE9uTjdXYXY2Z3R3SFFEd2lDamhJTnhZTmdkVW9tRHV4U3Q5dy00SEF4a2tlTWwzOFpUUzkyRXVkSXVNWklyY0l1RXdYQQ?oc=5","date":"2026-03-23","type":"patent","source":"Law360","summary":"Fresenius Challenges Patents To Launch IBD Drug Biosimilar - Law360","headline":"Fresenius Challenges Patents To Launch IBD Drug Biosimilar - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTDI0QXVXalpabWF3bm9PNlA2WGhTT2k0TkxXQkM5dHpyY21ySUJ2Z1NMTnVuc01WZThJbWU5QS1yRWhlYzRWX1NvR0F2V1NIZmF2XzhlMFoyOGMtb29iX1FQc0ZZSTJ2SlYxRmYwLUdBZFZtZG9qN2ZwSVpOSnAyMVBfcW1mWHZ1WEdrMkhURXBaLXZFTXA2cllmWlNocWxzNXVxSzdVbEI?oc=5","date":"2026-02-19","type":"patent","source":"JUVE Patent","summary":"No claim to damages for Millenium and Cilag in dispute over bortezomib - JUVE Patent","headline":"No claim to damages for Millenium and Cilag in dispute over bortezomib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQUmt4T1BmOEhubUFzeHZIZEZkLWRhbmVEWl9sTkRKTzFmUzNMZmZtT1ptNkxHYjFLRE5FQXZKejAwNWIxQTRaNUpPb0oxNUtHUlkwUTAxZ1ItSVZBUW01M3N2SWt1ZTAwSUxJS2VEYlRaekE2VTlHZlZJazFoNDhPMmhYYTdvV0pyOVFsdVBMMjhZV3VMZGNuWTRvZzBNRGlGYnJjcW9TTWpkS005eFUyby13UUdMelpSTXlla0NBc3JIN2Z5WWM5ajNxOHFEOUJwUUF0dDBmYjJ0alFBSzJTMk1rV0Y5ek1xTlE?oc=5","date":"2025-11-19","type":"pipeline","source":"Elicio Therapeutics","summary":"Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer - Elicio Therapeutics","headline":"Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQMDdQdVJ3MjdVTjhqak5EYmU5dEJsRjZ0TmhleFlyemUwWXVQNEN3enRkMDVYeWgzZ0doN0h2QTZYQnZ2NEZ6T1Rwd3BwSHdCanV6TV9XNGR2NkRScWs0LU9BT0swWll6M1YyTWdjZi1zRnB3b2dEZ0QyNTJ0LTlUcDhyZ0NBaUxGcW9vSlpfbE5hb2RzNXp6NDBzdklDR2IyUy0xdk1ONktZTDJG?oc=5","date":"2025-11-05","type":"pipeline","source":"Contract Pharma","summary":"Aktis Oncology Appoints Kyle Kuvalanka Chief Financial Officer - Contract Pharma","headline":"Aktis Oncology Appoints Kyle Kuvalanka Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQeGp3UUEwQzNuZmZmVGllYkJPZzZTU2VOOEY5WFI5YWZOODdXdTktcmdseWJ0bUFJcHVxNHBRZ1U1OHA1QnB1U0FjaFZrWS1ITjFiVGQwRDB6dVg2VHViYUlVa1NfVjFmMEJad1dEUk1fMURadmZ2RUNLeF9EdEIyeFBOY3lhVEgyTmctdTY0RHl4Rjg?oc=5","date":"2025-09-15","type":"pipeline","source":"Yahoo Finance","summary":"Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight - Yahoo Finance","headline":"Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOMlBwS1Q5U3VDYVROSTF3akJWcDRxNkVHcldHSVdYQWNzOHJkRTlSckJoYmpsX2RZazF1WkpqdVRUb0JaT1p0Qlg0TU5Yd1NQZjFqcGVJbnVYcnUwR3hJem83dzJKcVNYSW9fMFE4VU9JS1dQVkxWTGFpVkxTQkJjWlZJZlFid2Q4VWhv?oc=5","date":"2024-06-07","type":"pipeline","source":"Dallas Innovates","summary":"Irving’s McKesson Corp. Adds Healthcare Veteran to Board - Dallas Innovates","headline":"Irving’s McKesson Corp. Adds Healthcare Veteran to Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9RdkFNdHBhME40djFMV1lDaElCay14XzNMUE13eGIwZzR1b2lmN3ZuSGoyNmNDUUMxT2duY2ZrQ2J5TWFFXzdEQ3F0Z2x5cXBHZTNacnhR?oc=5","date":"2018-06-07","type":"pipeline","source":"Nature","summary":"People - Nature","headline":"People","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE00NFlyaU1jSG1TamxMaS1NWXZCRmdTUmFkWTd6MlpYX1JyOUxrbUpVX1lWcGpKc1laYTVyVlp3MUZDSTFoaFFobG1JeHNzTERnSjB5ZG9nb2R6ZUU?oc=5","date":"2018-04-19","type":"pipeline","source":"Drugwatch.com","summary":"Takeda Pharmaceuticals | Products, Recalls & Controversies - Drugwatch.com","headline":"Takeda Pharmaceuticals | Products, Recalls & Controversies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPX1lkakI0Q3JScEI1YWY0b0JlQ0w2TVFtWHlwTDRUUzJOb1JjWDlqZksxVE5wR2JfdzQxWkJGV3Z3QkVWYjF2cGpiX0FYY3lycGxKb2VIcTMzZXlOeFAxNlBERGNCZU9hNXQ2M0NLcEhvbTdmZkdOeFhrY3ZOSm5TT2JVd0R5NWhMUWJWWU5PMUtUalNPMDRRa0hNSTJNVjBEUmZVb1VYWmV4S2hPaTM5SFpHb0RNSW5n?oc=5","date":"2017-08-10","type":"pipeline","source":"IPWatchdog.com","summary":"Inherent obviousness necessitates specific motivation to modify lead compound in pharma process due to surprising, unexpected results - IPWatchdog.com","headline":"Inherent obviousness necessitates specific motivation to modify lead compound in pharma process due to surprising, unexp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOOFhEeHdId2lZQXRFcWtTVDlZWnNlVV9KZWowN0ZzS2VNell0TzF4REV1bEJkTzdjdWt6TlNsakFacWh0WU8tQnRFNENIQjJRNFJHd2E1X190VktUT0hJcmVJMG8yZWxOSWJ4aHdiM0tlYlMyZWpEWFp3YlZWZlpzQmNUS1hqaktfNmFVY0c5ZWxYcFk1Rk56WUZ6TnFkUXM?oc=5","date":"2017-07-21","type":"pipeline","source":"Procopio","summary":"Millennium Case May Strengthen IP Portfolios of Pharma Companies - Procopio","headline":"Millennium Case May Strengthen IP Portfolios of Pharma Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE54MW9Nck9heFkwVHkyWEk2dElIVEIwcVdEMkRxWWpoa1Q4M1k1SjRUWHRhSWtOT0ZadzdBTGRDX0N2QVU1TVlyczhDbkdyZ3A5WDJFeHcwX3hkM0p5cHc?oc=5","date":"2008-04-11","type":"pipeline","source":"WSJ","summary":"Takeda to Pay Billions to Get Into Biotech - WSJ","headline":"Takeda to Pay Billions to Get Into Biotech","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":3,"phase_1":2,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}